6 August 2021 (Friday) - ASH Update

The nice people at the American Society of Hematology sent an update on haemostasis today. I’ve mentioned before that I struggle to find CPD material which focusses on haemostasis, so this was rather useful.

 Here are the highlights in bleeding disorders:

Evaluating Two New Options for Hereditary Hemorrhagic Telangiectasia
At EHA2021 Virtual, researchers shared safety and efficacy findings of two agents for the treatment of the rare disease hereditary hemorrhagic telangiectasia: pazopanib and bevacizumab.
Hematologica Obscura
The prevalence of afibrinogenemia is approximately one in 1,000,000, making the bleeding disorder much rarer than either type of hemophilia and difficult to diagnose.
Outcomes After ABO-Incompatible Platelet Transfusions in Patients With Intracerebral Hemorrhage
The use of an incompatible platelet unit led to suboptimal platelet recovery and worse in-hospital outcomes at discharge compared with patients who received ABO-compatible transfusions.


No comments:

Post a Comment